Alexion maintained at buy by Merrill

Merrill Lynch analyst David Munno kept Alexion Pharmaceuticals Inc. at a buy rating. Alexion submitted its Biologics License Application for Soliris for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to the Food and Drug Administration about six weeks earlier than expected. Merrill anticipates a priority review since PNH is a rare orphan disease. In addition, data from the phase 3 Triumph trial of Soliris were published in the New England Journal of Medicine indicating broad efficacy across all patients and better stabilization of hemoglobin. Shares of the Cheshire, Conn.-based biotechnology company were down 63 cents, or 1.89%, at $32.79. (Nasdaq: ALXN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.